Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $7.3 million.

  • CG Oncology's Share-based Compensation rose 17674.59% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year increase of 24045.9%. This contributed to the annual value of $11.4 million for FY2024, which is 64620.42% up from last year.
  • CG Oncology's Share-based Compensation amounted to $7.3 million in Q3 2025, which was up 17674.59% from $7.0 million recorded in Q2 2025.
  • CG Oncology's 5-year Share-based Compensation high stood at $7.3 million for Q3 2025, and its period low was $177000.0 during Q2 2023.
  • Over the past 3 years, CG Oncology's median Share-based Compensation value was $2.2 million (recorded in 2024), while the average stood at $2.9 million.
  • As far as peak fluctuations go, CG Oncology's Share-based Compensation surged by 116892.66% in 2024, and later surged by 17674.59% in 2025.
  • CG Oncology's Share-based Compensation (Quarter) stood at $778000.0 in 2023, then soared by 541.39% to $5.0 million in 2024, then soared by 46.91% to $7.3 million in 2025.
  • Its last three reported values are $7.3 million in Q3 2025, $7.0 million for Q2 2025, and $5.2 million during Q1 2025.